Deckchairs in Regent’s Park, London

It’s the dog days of summer and time for a mini-series with some expert interviews to enjoy while sitting in your “strandkorb” (classic German beach deck chair) in a Baltic sea resort, or wherever you’re chilling out.

It’s remarkable to see how the field of cell therapy continues to grow. Today and in coming weeks, we are taking a closer look at innovative ways companies are seeking to leverage the unique properties of Natural Killer (NK) cells.

Who will build the best CAR-NK construct?

Cell therapy remains one of the hottest areas for innovation. At this year’s annual AACR meeting (AACR22) we saw a lot of new data from companies in the field of CAR modified Natural Killer (NK cells).

We’re all familiar with the concept of putting a chimeric antigen receptor (CAR) on a T cell (CAR-T), so why not put a CAR on a NK cell to target it against tumors as well?

There’s certainly a lot of interest in this approach and as a result, the CAR-NK cell therapy landscape is fast-moving. We expect to see a lot more data and news roll out in the coming years, as companies look to bring new products into the clinic.

Recently we spoke with experts at three CAR-NK companies who had data at the 2022 AACR annual meeting – to be clear we’re not endorsing any of them, but each company offered a different scientific approach and perspective offering insights into the challenges and opportunities of this emerging field.

First up in our latest mini-series is Dr Bob Hollingsworth, Chief Scientific Officer of Shoreline Biosciences, a company who are looking to develop induced pluripotent stem cell (iPSC) derived NK cell therapies.

BSB readers can login to read our latest expert interview to find out more about their scientific approach or you can purchase access.

This content is restricted to subscribers

Posted by